🇺🇸 FDA
Patent

US 8956828

Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

granted A61KA61K2239/48A61K35/00

Quick answer

US patent 8956828 (Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases) held by Sangamo Biosciences, Inc. expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Biosciences, Inc.
Grant date
Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2239/48, A61K35/00, A61K35/28, A61K38/00